208 related articles for article (PubMed ID: 22189416)
1. Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott-Aldrich syndrome.
Catucci M; Prete F; Bosticardo M; Castiello MC; Draghici E; Locci M; Roncarolo MG; Aiuti A; Benvenuti F; Villa A
Gene Ther; 2012 Dec; 19(12):1150-8. PubMed ID: 22189416
[TBL] [Abstract][Full Text] [Related]
2. B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome.
Castiello MC; Scaramuzza S; Pala F; Ferrua F; Uva P; Brigida I; Sereni L; van der Burg M; Ottaviano G; Albert MH; Grazia Roncarolo M; Naldini L; Aiuti A; Villa A; Bosticardo M
J Allergy Clin Immunol; 2015 Sep; 136(3):692-702.e2. PubMed ID: 25792466
[TBL] [Abstract][Full Text] [Related]
3. Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome.
Bosticardo M; Draghici E; Schena F; Sauer AV; Fontana E; Castiello MC; Catucci M; Locci M; Naldini L; Aiuti A; Roncarolo MG; Poliani PL; Traggiai E; Villa A
J Allergy Clin Immunol; 2011 Jun; 127(6):1376-84.e5. PubMed ID: 21531013
[TBL] [Abstract][Full Text] [Related]
4. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
[TBL] [Abstract][Full Text] [Related]
5. Improvement of migratory defects in a murine model of Wiskott-Aldrich syndrome gene therapy.
Blundell MP; Bouma G; Calle Y; Jones GE; Kinnon C; Thrasher AJ
Mol Ther; 2008 May; 16(5):836-44. PubMed ID: 18388921
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome.
Astrakhan A; Sather BD; Ryu BY; Khim S; Singh S; Humblet-Baron S; Ochs HD; Miao CH; Rawlings DJ
Blood; 2012 May; 119(19):4395-407. PubMed ID: 22431569
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic-specific lentiviral vectors circumvent cellular toxicity due to ectopic expression of Wiskott-Aldrich syndrome protein.
Toscano MG; Frecha C; Benabdellah K; Cobo M; Blundell M; Thrasher AJ; García-Olivares E; Molina IJ; Martin F
Hum Gene Ther; 2008 Feb; 19(2):179-97. PubMed ID: 18240968
[TBL] [Abstract][Full Text] [Related]
8. Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction.
Dupré L; Trifari S; Follenzi A; Marangoni F; Lain de Lera T; Bernad A; Martino S; Tsuchiya S; Bordignon C; Naldini L; Aiuti A; Roncarolo MG
Mol Ther; 2004 Nov; 10(5):903-15. PubMed ID: 15509508
[TBL] [Abstract][Full Text] [Related]
9. Improved lentiviral vectors for Wiskott-Aldrich syndrome gene therapy mimic endogenous expression profiles throughout haematopoiesis.
Frecha C; Toscano MG; Costa C; Saez-Lara MJ; Cosset FL; Verhoeyen E; Martin F
Gene Ther; 2008 Jun; 15(12):930-41. PubMed ID: 18323794
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation.
Dupré L; Marangoni F; Scaramuzza S; Trifari S; Hernández RJ; Aiuti A; Naldini L; Roncarolo MG
Hum Gene Ther; 2006 Mar; 17(3):303-13. PubMed ID: 16544979
[TBL] [Abstract][Full Text] [Related]
11. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice.
Charrier S; Stockholm D; Seye K; Opolon P; Taveau M; Gross DA; Bucher-Laurent S; Delenda C; Vainchenker W; Danos O; Galy A
Gene Ther; 2005 Apr; 12(7):597-606. PubMed ID: 15616597
[TBL] [Abstract][Full Text] [Related]
12. Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome.
Scaramuzza S; Biasco L; Ripamonti A; Castiello MC; Loperfido M; Draghici E; Hernandez RJ; Benedicenti F; Radrizzani M; Salomoni M; Ranzani M; Bartholomae CC; Vicenzi E; Finocchi A; Bredius R; Bosticardo M; Schmidt M; von Kalle C; Montini E; Biffi A; Roncarolo MG; Naldini L; Villa A; Aiuti A
Mol Ther; 2013 Jan; 21(1):175-84. PubMed ID: 22371846
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic lineage cell-specific protein 1 functions in concert with the Wiskott-Aldrich syndrome protein to promote podosome array organization and chemotaxis in dendritic cells.
Dehring DA; Clarke F; Ricart BG; Huang Y; Gomez TS; Williamson EK; Hammer DA; Billadeau DD; Argon Y; Burkhardt JK
J Immunol; 2011 Apr; 186(8):4805-18. PubMed ID: 21398607
[TBL] [Abstract][Full Text] [Related]
14. Development of lentiviral gene therapy for Wiskott Aldrich syndrome.
Galy A; Roncarolo MG; Thrasher AJ
Expert Opin Biol Ther; 2008 Feb; 8(2):181-90. PubMed ID: 18194074
[TBL] [Abstract][Full Text] [Related]
15. Comparison of insulators and promoters for expression of the Wiskott-Aldrich syndrome protein using lentiviral vectors.
Koldej RM; Carney G; Wielgosz MM; Zhou S; Zhan J; Sorrentino BP; Nienhuis AW
Hum Gene Ther Clin Dev; 2013 Jun; 24(2):77-85. PubMed ID: 23786330
[TBL] [Abstract][Full Text] [Related]
16. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients.
Charrier S; Dupré L; Scaramuzza S; Jeanson-Leh L; Blundell MP; Danos O; Cattaneo F; Aiuti A; Eckenberg R; Thrasher AJ; Roncarolo MG; Galy A
Gene Ther; 2007 Mar; 14(5):415-28. PubMed ID: 17051251
[TBL] [Abstract][Full Text] [Related]
17. Lentiviral-mediated gene therapy restores B cell tolerance in Wiskott-Aldrich syndrome patients.
Pala F; Morbach H; Castiello MC; Schickel JN; Scaramuzza S; Chamberlain N; Cassani B; Glauzy S; Romberg N; Candotti F; Aiuti A; Bosticardo M; Villa A; Meffre E
J Clin Invest; 2015 Oct; 125(10):3941-51. PubMed ID: 26368308
[TBL] [Abstract][Full Text] [Related]
18. Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models.
Marangoni F; Bosticardo M; Charrier S; Draghici E; Locci M; Scaramuzza S; Panaroni C; Ponzoni M; Sanvito F; Doglioni C; Liabeuf M; Gjata B; Montus M; Siminovitch K; Aiuti A; Naldini L; Dupré L; Roncarolo MG; Galy A; Villa A
Mol Ther; 2009 Jun; 17(6):1073-82. PubMed ID: 19259069
[TBL] [Abstract][Full Text] [Related]
19. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome.
Aiuti A; Biasco L; Scaramuzza S; Ferrua F; Cicalese MP; Baricordi C; Dionisio F; Calabria A; Giannelli S; Castiello MC; Bosticardo M; Evangelio C; Assanelli A; Casiraghi M; Di Nunzio S; Callegaro L; Benati C; Rizzardi P; Pellin D; Di Serio C; Schmidt M; Von Kalle C; Gardner J; Mehta N; Neduva V; Dow DJ; Galy A; Miniero R; Finocchi A; Metin A; Banerjee PP; Orange JS; Galimberti S; Valsecchi MG; Biffi A; Montini E; Villa A; Ciceri F; Roncarolo MG; Naldini L
Science; 2013 Aug; 341(6148):1233151. PubMed ID: 23845947
[TBL] [Abstract][Full Text] [Related]
20. Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome.
Sereni L; Castiello MC; Di Silvestre D; Della Valle P; Brombin C; Ferrua F; Cicalese MP; Pozzi L; Migliavacca M; Bernardo ME; Pignata C; Farah R; Notarangelo LD; Marcus N; Cattaneo L; Spinelli M; Giannelli S; Bosticardo M; van Rossem K; D'Angelo A; Aiuti A; Mauri P; Villa A
J Allergy Clin Immunol; 2019 Sep; 144(3):825-838. PubMed ID: 30926529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]